Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin, Ireland.
School of Medicine, University College Dublin, Dublin, Ireland.
Respirology. 2022 Jul;27(7):539-548. doi: 10.1111/resp.14278. Epub 2022 May 5.
The last 2 years have presented previously unforeseen challenges in pulmonary medicine. Despite the significant impact of the SARS-CoV-2 pandemic on patients, clinicians and communities, advances in the care and understanding of interstitial lung disease (ILD) continued unabated. Recent studies have led to improved guidelines, better understanding of the role for antifibrotics in fibrosing ILDs, prognostic indicators and novel biomarkers. In this concise contemporary review, we summarize many of the important studies published in 2021, highlighting their relevance and impact to the management and knowledge of ILD.
过去 2 年，肺部医学面临了前所未有的挑战。尽管 SARS-CoV-2 大流行对患者、临床医生和社区造成了重大影响，但间质性肺疾病（ILD）的护理和认识方面的进展仍在继续。最近的研究导致了更好的指南、对纤维化性ILD 中抗纤维化药物作用的更好理解、预后指标和新的生物标志物。在这篇简明的当代综述中，我们总结了 2021 年发表的许多重要研究，强调了它们与ILD 管理和知识的相关性和影响。
